6 November 2026RSS feed
PR●Press Release IndiaTHE BUSINESS ANNOUNCEMENT WIRE
Business announcements.
Direct from the source.
NEWSROOM / INDIA

The latest on the wire

Announcements from businesses shaping what comes next.

UPDATED THROUGHOUT THE DAY
Business wire19128

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed